CRTHF.US CARsgen Therapeutics Holdings Limited

Healthcare Biotechnology USA Stocks
1.42 USD
Close of Nov 14, 2026
0.7600 2.20
Market cap
USD 809M
P/E
-
P/B
4.66x
ROE
-12.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Oct 2025.

Is CRTHF.US undervalued?

Graham number

The Graham number of CARsgen Therapeutics Holdings Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CARsgen Therapeutics Holdings Limited fundamental analysis

No fundamental analysis for CARsgen Therapeutics Holdings Limited yet.

CARsgen Therapeutics Holdings Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma. It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin…

Full company profile